Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Northwestern University

Headquarters: Evanston, IL, United States of America
Year Founded: 1850
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Nov 7, 2024
Discovery & Translation

Science Spotlight: Multi-epitope antivirals, metastatic transition, and more

BioCentury’s roundup of translational innovations also includes a study from Amgen and a newco spotlight
BioCentury | Aug 2, 2024
Distillery Therapeutics

Increasing hexosamine synthesis for α-synucleinopathies

BioCentury | Feb 10, 2024
Discovery & Translation

Science spotlight: Moonlight’s enhanced T cells; plus a HUNK inhibitor and more

BioCentury’s roundup of translational innovations
BioCentury | Dec 15, 2023
Discovery & Translation

New targets at ASH point to AML combos, continued sickle cell interest 

Innovation in protein degradation also on display, while immunotherapy targets are notably absent 
BioCentury | Oct 25, 2023
Finance

Oct. 25 Quick Takes: U.K. takes next step in pension fund reforms

Plus: CBC-backed R-Bridge realizes royalty exit, and updates from Akebia, DermBiont, GSK and Flashpoint
BioCentury | Oct 13, 2023
Discovery & Translation

eGenesis’ kidney xenotransplant; plus Epirium, Neurimmune and more

BioCentury’s roundup of translational innovations
BioCentury | Sep 22, 2023
Distillery Therapeutics

Inhibiting TFPI2 for glioblastoma

BioCentury | Sep 14, 2023
Regulation

FDA to weigh how broadly to expand label for Alnylam’s Onpattro

FDA panel votes 9-3 that the benefits of Onpattro to treat ATTR cardiomyopathy outweigh risks
BioCentury | Sep 12, 2023
Discovery & Translation

Lurie winners show mitochondria is more than a powerhouse

Northwestern’s Navdeep Chandel and Harvard’s Vamsi Mootha share the FNIH’s 2023 prize for pioneering mitochondrial biology beyond ATP
BioCentury | Jul 7, 2023
Discovery & Translation

Smaller gene editors, Resilience’s cell-free antibody discovery platform and more

BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 274